Skip to product information
1 of 1

  • Images are for illustration purposes only
  • Gphc Registered
  • Join over 100k customers
  • Fixed prices and no subscriptions
  • Discreet next day delivery.
  • Free shipping on all orders over £50

Azzaro Chrome Aqua 100ml Eau De Toilette EDT Spray

Azzaro Chrome Aqua 100ml Eau De Toilette EDT Spray

  • 1. Ozempic®️-equivalent therapy now available for weight management
  • 2. Average weight loss of 17%, with 1 in 3 patients achieving over 20%
  • 3. May help reduce osteoarthritis-related pain
  • 4. Wegovy®️ is not expected to impact the effectiveness of oral contraceptives
  • 5. Supports cardiovascular risk reduction
  • 6. Over 22 million patients treated with semaglutide-based therapies since 2018

We’re proud to offer fast and discreet delivery for all our medicines & treatments.

Price Checker

Regular price £54.00
Sale price £54.00
Sale Sold out
  • Lowest price guarantee
  • Includes FREE private prescription
View full details

Azzaro Chrome Aqua presents a fresh and invigorating interpretation of the original Chrome fragrance through its vibrant scent. The 100ml Eau de Toilette spray embodies the essence of unbridled freedom and natural connection by uniting aquatic freshness with refined wood notes. The scent begins with green apple and grapefruit notes which create an immediate sensory stimulation. The fragrance develops its marine freshness through basil and sea notes before vetiver and cypress establish its earthy foundation and masculine sophistication. The signature Chrome bottle now features an aqua-blue twist which contains this scent designed for modern men who want a clean fragrance that lasts throughout the day and night.

Fragrance Notes: Top: Grapefruit, Green Apple Heart: Basil, Sea Notes Base: Vetiver, Cypress

Key Features: Fresh, aquatic, and aromatic scent This fragrance suits daily use particularly during hot weather months. The 100ml spray bottle provides extended usage. Azzaro Chrome Aqua brings ocean freshness to life through its elegant scent which unites freshness with elegance.

Patient Information Leaflet

Important - Before taking any medication, it is always important to read the Patient Information Leaflet (PIL)

Written and reviewed by our qualified team

GPhC Number: 2233073
Tarun Kumar

Reviewed by:

Tarun Kumar

Superintendent/ Clinical Lead

📖 Find out more about our team of medical content authors and how we ensure the accuracy of our content with our content guidelines.

Content last updated: 31 Mar 2025

We’re a safe and
regulated UK service

Registered Pharmacy Badge

Lowest Price Guarantee

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

100% discreet packaging

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

Agent

Need help?
Talk to our friendly experts now

How our service works

Service Setup

Service setup

Discreet Packaging

Discreet packaging

Express Delivery

Express delivery

Comparison of Weight Loss Injectables

Features

Mounjaro®

Injectable Pen

Wegovy®

Injectable Pen

Saxenda®

Injectable Pen

Active Ingredient Tirzepatide Semaglutide Liraglutide
Mechanism of Action GLP-1 and GIP receptor agonist GLP-1 receptor agonist GLP-1 receptor agonist
Administration Weekly injection Weekly injection Daily injection
Dosage Varies by patient, typically starting low Varies, typically starting at 0.25 mg Varies, starting at 0.6 mg
Effect on Appetite Significantly reduces appetite and cravings Reduces appetite and increases satiety Reduces appetite and increases satiety
Average Weight Loss Up to 20% body weight reduction Up to 15% body weight reduction Significant weight reduction
Side Effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation Nausea, diarrhoea, constipation, hypoglycemia
Approval FDA-approved for weight loss FDA-approved for weight loss FDA-approved for weight loss
Suitable For Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities